
Cancer Supportive Care Drugs Market by Therapeutic Class (Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents), Application (Breast Cancer, Colorectal Cancer, Liver Cancer) - Global Forecast 2024-2030
Description
Cancer Supportive Care Drugs Market by Therapeutic Class (Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents), Application (Breast Cancer, Colorectal Cancer, Liver Cancer) - Global Forecast 2024-2030
The Cancer Supportive Care Drugs Market size was estimated at USD 20.62 billion in 2023 and expected to reach USD 21.46 billion in 2024, at a CAGR 4.50% to reach USD 28.06 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cancer Supportive Care Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Supportive Care Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cancer Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Cancer Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Therapeutic Class
Antiemetics
Bisphosphonates
Erythropoiesis Stimulating Agents
Granulocyte-Colony Stimulating Factors
Non-Steroidal Anti-Inflammatory Drugs
Opioids
Application
Breast Cancer
Colorectal Cancer
Liver Cancer
Lung Cancer
Prostate Cancer
Stomach Cancer
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Cancer Supportive Care Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Supportive Care Drugs Market?
3. What are the technology trends and regulatory frameworks in the Cancer Supportive Care Drugs Market?
4. What is the market share of the leading vendors in the Cancer Supportive Care Drugs Market?
5. Which modes and strategic moves are suitable for entering the Cancer Supportive Care Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Cancer Supportive Care Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
- 5.1.1.2. Increasing approval and launch of new products
- 5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
- 5.1.2. Restraints
- 5.1.2.1. High cost of cancer supportive care drugs
- 5.1.3. Opportunities
- 5.1.3.1. Development of novel targeted therapies for the treatment of cancer
- 5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
- 5.1.4. Challenges
- 5.1.4.1. Side effects associated with consumption of drugs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Cancer Supportive Care Drugs Market, by Therapeutic Class
- 6.1. Introduction
- 6.2. Antiemetics
- 6.3. Bisphosphonates
- 6.4. Erythropoiesis Stimulating Agents
- 6.5. Granulocyte-Colony Stimulating Factors
- 6.6. Non-Steroidal Anti-Inflammatory Drugs
- 6.7. Opioids
- 7. Cancer Supportive Care Drugs Market, by Application
- 7.1. Introduction
- 7.2. Breast Cancer
- 7.3. Colorectal Cancer
- 7.4. Liver Cancer
- 7.5. Lung Cancer
- 7.6. Prostate Cancer
- 7.7. Stomach Cancer
- 8. Americas Cancer Supportive Care Drugs Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Cancer Supportive Care Drugs Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Acacia Pharma Group PLC
- 12.1.2. Amgen Inc.
- 12.1.3. Aphios Corporation
- 12.1.4. AstraZeneca PLC
- 12.1.5. Bayer AG
- 12.1.6. Celldex Therapeutics
- 12.1.7. GSK PLC
- 12.1.8. Helsinn Healthcare SA
- 12.1.9. Heron Pharma
- 12.1.10. Ipsen Pharma
- 12.1.11. Johnson & Johnson
- 12.1.12. Merck & Co.
- 12.1.13. Novartis International AG
- 12.1.14. Sanofi SA
- 12.1.15. Sun Pharmaceutical Industries Ltd.
- 12.1.16. Teva Pharmaceutical Industries Ltd.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
- FIGURE 7. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
- FIGURE 8. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.